Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/52040
DC FieldValueLanguage
dc.contributor.authorWägner, A. M.en_US
dc.contributor.authorMartínez-Rubio, A.en_US
dc.contributor.authorOrdóez-Llanos, J.en_US
dc.contributor.authorPérez-Pérez, A.en_US
dc.date.accessioned2018-11-25T16:56:33Z-
dc.date.available2018-11-25T16:56:33Z-
dc.date.issued2002en_US
dc.identifier.issn0953-6205en_US
dc.identifier.urihttp://hdl.handle.net/10553/52040-
dc.description.abstractDiabetes is associated with a high incidence and poor prognosis of cardiovascular disease, and with high short- and long-term mortality. Adequate treatment of cardiovascular disorders and aggressive management of coexisting risk factors have proved to be at least as effective in diabetic as in nondiabetic patients in randomized, controlled studies. Indeed, treating diabetic patients with cardiovascular disease results in a larger absolute risk reduction than in nondiabetic subjects. Nevertheless, diabetic patients often receive inadequate therapy, which may, to a certain extent, explain their poor prognosis. Recommendations for the treatment of diabetic patients with acute myocardial infarction should include beta-blockers, aspirin, and ACE-inhibitors in all patients in whom no specific contraindications exist. Fibrinolysis should be administered when indicated, and the benefits of improving glycemic control should not be forgotten either. In patients with multi-vessel disease who need revascularization, when selecting the type of procedure, the superiority of surgical revascularization over angioplasty should be borne in mind. Even heart transplantation should be included as a therapeutic option since there are no data to support the exclusion of patients on account of their diabetes. Finally, coexisting risk factors should be intensively treated through lifestyle intervention, with or without drug therapy, in order to achieve secondary prevention goals.en_US
dc.languageengen_US
dc.relation.ispartofEuropean Journal of Internal Medicineen_US
dc.sourceEuropean Journal of Internal Medicine[ISSN 0953-6205],v. 13(1), p. 15-30 (Febrero 2022)en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject320704 Patología cardiovascularen_US
dc.subject.otherCardiovascular diseaseen_US
dc.subject.otherDiabetes mellitusen_US
dc.subject.otherTreatmenten_US
dc.subject.otherSecondary preventionen_US
dc.titleDiabetes mellitus and cardiovascular diseaseen_US
dc.typeinfo:eu-repo/semantics/reviewen_US
dc.typeReviewen_US
dc.identifier.doi10.1016/S0953-6205(01)00194-7en_US
dc.identifier.scopus0036172631-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid55663792400-
dc.contributor.authorscopusid6508307652-
dc.contributor.authorscopusid7003385726-
dc.description.lastpage30en_US
dc.description.firstpage15en_US
dc.relation.volume13en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Reseñaen_US
dc.description.numberofpages16en_US
dc.utils.revisionen_US
dc.date.coverdateFebrero 2002en_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.scieSCIE-
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
Appears in Collections:Reseña
Show simple item record

SCOPUSTM   
Citations

14
checked on Nov 17, 2024

Page view(s)

86
checked on Sep 21, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.